{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-26-000063","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2026-07-23T11:00:14+00:00","discovered_at":"2026-07-23T11:05:00.283455+00:00","generated_at":"2026-07-23T11:05:44.569331+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Novocure Q2 net revenue $183.6M (+16% YoY); raises FY 2026 guidance","bullets":["Net revenue $183.6M, up 16% YoY; net loss $15.7M ($0.13 loss per share).","Adjusted EBITDA $10.8M; gross margin 78% vs 74% a year ago.","FY 2026 revenue guidance raised to $710M-$725M (prev $690M-$710M); adjusted EBITDA guidance raised to $0M-$15M.","CE Mark received for Optune Pax for locally advanced pancreatic cancer; 285 active patients on Optune Pax in U.S.","Global active patients 5,128, up 11% YoY for Optune Gio; Optune Lua active patients up 51%."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-26-000063","json":"https://secwatch.observer/filing/0001645113-26-000063.json","markdown":"https://secwatch.observer/filing/0001645113-26-000063.md","text":"https://secwatch.observer/filing/0001645113-26-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000063/0001645113-26-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000063/nvcr-20260723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-23T11:05:44.569331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}